Form 4: Guardant Health Director Vijaya Gadde Reports Significant Equity Grant

Guardant Health, Inc. Director Vijaya Gadde has reported the acquisition of stock options and restricted stock units, granted on June 18, 2025, as part of her compensation.

Summary

• Vijaya Gadde, a Director of Guardant Health, Inc. (GH), reported the acquisition of equity securities.
• The filing details the grant of 6,833 stock options with an exercise price of $50.57 per share.
• Additionally, 4,203 Restricted Stock Units (RSUs) were granted.
• Both the stock options and RSUs were granted on June 18, 2025.
• The stock options are set to expire on June 18, 2035.
• Both the stock options and RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next annual stockholders meeting, whichever is earlier.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity compensation grant to a director, which is generally viewed positively as it aligns management's interests with shareholders.

Positives

• The grant of equity compensation (stock options and restricted stock units) to Director Vijaya Gadde aligns her interests with those of shareholders, incentivizing long-term company performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent transaction.

Future Outlook

The stock options and restricted stock units are scheduled to vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next annual stockholders meeting, whichever is earlier.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across industries to align executive and director interests with shareholder value. It does not provide broader industry trend insights.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a standard form of equity compensation in publicly traded companies, particularly in the biotechnology and healthcare sectors, aimed at incentivizing long-term performance and retention. Specific comparisons to other companies' compensation packages are not detailed in this filing.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a director aligns their interests with shareholders, potentially leading to improved long-term performance and value creation.

Next Steps

• Vesting of 6,833 stock options and 4,203 restricted stock units on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, insider transaction, equity compensation, stock options, restricted stock units, director compensation, Vijaya Gadde